Back to Search Start Over

Postmortem toxicology findings from the Camden Opioid Research Initiative.

Authors :
Kusic DM
Heil J
Zajic S
Brangan A
Dairo O
Heil S
Feigin G
Kacinko S
Buono RJ
Ferraro TN
Rafeq R
Haroz R
Baston K
Bodofsky E
Sabia M
Salzman M
Resch A
Madzo J
Scheinfeldt LB
Issa JJ
Jelinek J
Source :
PloS one [PLoS One] 2023 Nov 01; Vol. 18 (11), pp. e0292674. Date of Electronic Publication: 2023 Nov 01 (Print Publication: 2023).
Publication Year :
2023

Abstract

The United States continues to be impacted by decades of an opioid misuse epidemic, worsened by the COVID-19 pandemic and by the growing prevalence of highly potent synthetic opioids (HPSO) such as fentanyl. In instances of a toxicity event, first-response administration of reversal medications such as naloxone can be insufficient to fully counteract the effects of HPSO, particularly when there is co-occurring substance use. In an effort to characterize and study this multi-faceted problem, the Camden Opioid Research Initiative (CORI) has been formed. The CORI study has collected and analyzed post-mortem toxicology data from 42 cases of decedents who expired from opioid-related toxicity in the South New Jersey region to characterize substance use profiles. Co-occurring substance use, whether by intent or through possible contamination of the illicit opioid supply, is pervasive among deaths due to opioid toxicity, and evidence of medication-assisted treatment is scarce. Nearly all (98%) of the toxicology cases show the presence of the HPSO, fentanyl, and very few (7%) results detected evidence of medication-assisted treatment for opioid use disorder, such as buprenorphine or methadone, at the time of death. The opioid toxicity reversal drug, naloxone, was detected in 19% of cases, but 100% of cases expressed one or more stimulants, and sedatives including xylazine were detected in 48% of cases. These results showing complex substance use profiles indicate that efforts at mitigating the opioid misuse epidemic must address the complications presented by co-occurring stimulant and other substance use, and reduce barriers to and stigmas of seeking effective medication-assisted treatments.<br />Competing Interests: The authors have declared that no competing interests exist.<br /> (Copyright: © 2023 Kusic et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)

Details

Language :
English
ISSN :
1932-6203
Volume :
18
Issue :
11
Database :
MEDLINE
Journal :
PloS one
Publication Type :
Academic Journal
Accession number :
37910493
Full Text :
https://doi.org/10.1371/journal.pone.0292674